-
1
-
-
0041435762
-
-
Atlanta, GA: American Cancer Society
-
Cancer Facts and Figures 2013. Atlanta, GA: American Cancer Society; 2013:.
-
(2013)
Cancer Facts and Figures 2013
-
-
-
2
-
-
33846869083
-
Epidemiology and pathophysiology of obesity as cause of cancer
-
Ceschi M,Gutzwiller F,Moch H,Eichholzer M,Probst-Hensch NM.Epidemiology and pathophysiology of obesity as cause of cancer.Swiss Med Wkly. 2007;137:50-56.
-
(2007)
Swiss Med Wkly
, vol.137
, pp. 50-56
-
-
Ceschi, M.1
Gutzwiller, F.2
Moch, H.3
Eichholzer, M.4
Probst-Hensch, N.M.5
-
3
-
-
33645523067
-
Prevalence of overweight and obesity in the United States, 1999-2004
-
Ogden CL,Carroll MD,Curtin LR,McDowell MA,Tabak CJ,Flegal KM.Prevalence of overweight and obesity in the United States, 1999-2004.JAMA. 2006;295:1549-1555.
-
(2006)
JAMA
, vol.295
, pp. 1549-1555
-
-
Ogden, C.L.1
Carroll, M.D.2
Curtin, L.R.3
McDowell, M.A.4
Tabak, C.J.5
Flegal, K.M.6
-
4
-
-
0346362456
-
Glimepiride pharmacokinetics in obese versus non-obese diabetic patients
-
Shukla UA,Chi EM,Lehr KH.Glimepiride pharmacokinetics in obese versus non-obese diabetic patients.Ann Pharmacother. 2004;38:30-35.
-
(2004)
Ann Pharmacother
, vol.38
, pp. 30-35
-
-
Shukla, U.A.1
Chi, E.M.2
Lehr, K.H.3
-
5
-
-
79955681195
-
An evaluation of the incidence of myelosuppression in obese patients with a capped body surface area
-
Lopes-Serrao MD,Gressett S,Hall R,Shah S.An evaluation of the incidence of myelosuppression in obese patients with a capped body surface area.J Oncol Pract. 2011;7:13-17.
-
(2011)
J Oncol Pract
, vol.7
, pp. 13-17
-
-
Lopes-Serrao, M.D.1
Gressett, S.2
Hall, R.3
Shah, S.4
-
6
-
-
33947320788
-
Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study
-
Modesitt SC,Tian C,Kryscio Ret al.Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study.Gynecol Oncol. 2007;105:59-65.
-
(2007)
Gynecol Oncol
, vol.105
, pp. 59-65
-
-
Modesitt, S.C.1
Tian, C.2
Kryscio, R.3
-
7
-
-
34247851095
-
Chemotherapy dose intensity and quality cancer care
-
Lyman GH.Chemotherapy dose intensity and quality cancer care.Oncology (Williston Park). 2006;20:16-25.
-
(2006)
Oncology (Williston Park)
, vol.20
, pp. 16-25
-
-
Lyman, G.H.1
-
8
-
-
0029824018
-
Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541
-
Rosner GL,Hargis JB,Hollis DRet al.Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541.J Clin Oncol. 1996;14:3000-3008.
-
(1996)
J Clin Oncol
, vol.14
, pp. 3000-3008
-
-
Rosner, G.L.1
Hargis, J.B.2
Hollis, D.R.3
-
9
-
-
0035004363
-
Are medical oncologists biased in their treatment of the large woman with breast cancer?
-
Madarnas Y,Sawka CA,Franssen E,Bjarnason GA.Are medical oncologists biased in their treatment of the large woman with breast cancer?.Breast Cancer Res Treat. 2001;66:123-133.
-
(2001)
Breast Cancer Res Treat
, vol.66
, pp. 123-133
-
-
Madarnas, Y.1
Sawka, C.A.2
Franssen, E.3
Bjarnason, G.A.4
-
10
-
-
1442332174
-
Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114
-
Meyerhardt JA,Tepper JE,Niedzwiecki Det al.Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114.J Clin Oncol. 2004;22:648-657.
-
(2004)
J Clin Oncol
, vol.22
, pp. 648-657
-
-
Meyerhardt, J.A.1
Tepper, J.E.2
Niedzwiecki, D.3
-
11
-
-
25144466036
-
Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index
-
Colleoni M,Li S,Gelber RDet al.Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index.Lancet. 2005;366:1108-1110.
-
(2005)
Lancet
, vol.366
, pp. 1108-1110
-
-
Colleoni, M.1
Li, S.2
Gelber, R.D.3
-
12
-
-
84862986506
-
Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline
-
Griggs JJ,Mangu PB,Anderson Het al.Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.J Clin Oncol. 2012;30:1553-1561.
-
(2012)
J Clin Oncol
, vol.30
, pp. 1553-1561
-
-
Griggs, J.J.1
Mangu, P.B.2
Anderson, H.3
-
13
-
-
84867600008
-
Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults
-
Pai MP.Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults.Pharmacotherapy. 2012;32:856-868.
-
(2012)
Pharmacotherapy
, vol.32
, pp. 856-868
-
-
Pai, M.P.1
-
14
-
-
84876262274
-
Weight drives caspofungin variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths
-
Hall RG,Swancutt MA,Meek C,Leff R,Gumbo T.Weight drives caspofungin variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths.Antimicrob Agents Chemother. 2013;27:2259-2264.
-
(2013)
Antimicrob Agents Chemother
, vol.27
, pp. 2259-2264
-
-
Hall, R.G.1
Swancutt, M.A.2
Meek, C.3
Leff, R.4
Gumbo, T.5
-
15
-
-
80054695467
-
Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people
-
Hall RG,Swancutt MA,Gumbo T.Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people.Antimicrob Agents Chemother. 2011;55:5107-5112.
-
(2011)
Antimicrob Agents Chemother
, vol.55
, pp. 5107-5112
-
-
Hall, R.G.1
Swancutt, M.A.2
Gumbo, T.3
-
16
-
-
84857183281
-
Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people
-
Hall RG,Swancutt MA,Meek C,Leff RD,Gumbo T.Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people.Antimicrob Agents Chemother. 2012;56:1502-1507.
-
(2012)
Antimicrob Agents Chemother
, vol.56
, pp. 1502-1507
-
-
Hall, R.G.1
Swancutt, M.A.2
Meek, C.3
Leff, R.D.4
Gumbo, T.5
-
17
-
-
67349205883
-
Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
-
Ekhart C,Rodenhuis S,Schellens JH,Beijnen JH,Huitema AD.Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?.Cancer Chemother Pharmacol. 2009;64:115-122.
-
(2009)
Cancer Chemother Pharmacol
, vol.64
, pp. 115-122
-
-
Ekhart, C.1
Rodenhuis, S.2
Schellens, J.H.3
Beijnen, J.H.4
Huitema, A.D.5
-
18
-
-
36048936308
-
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese
-
Sparreboom A,Wolff AC,Mathijssen RHet al.Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.J Clin Oncol. 2007;25:4707-4713.
-
(2007)
J Clin Oncol
, vol.25
, pp. 4707-4713
-
-
Sparreboom, A.1
Wolff, A.C.2
Mathijssen, R.H.3
-
19
-
-
28844446324
-
Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia
-
Herrington JD,Tran HT,Riggs MW.Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia.Cancer Chemother Pharmacol. 2006;57:241-247.
-
(2006)
Cancer Chemother Pharmacol
, vol.57
, pp. 241-247
-
-
Herrington, J.D.1
Tran, H.T.2
Riggs, M.W.3
-
20
-
-
0023270126
-
Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients
-
Powis G,Reece P,Ahmann DL,Ingle JN.Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients.Cancer Chemother Pharmacol. 1987;20:219-222.
-
(1987)
Cancer Chemother Pharmacol
, vol.20
, pp. 219-222
-
-
Powis, G.1
Reece, P.2
Ahmann, D.L.3
Ingle, J.N.4
-
21
-
-
0024367984
-
Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution
-
Lind MJ,Margison JM,Cerny T,Thatcher N,Wilkinson PM.Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution.Cancer Chemother Pharmacol. 1989;25:139-142.
-
(1989)
Cancer Chemother Pharmacol
, vol.25
, pp. 139-142
-
-
Lind, M.J.1
Margison, J.M.2
Cerny, T.3
Thatcher, N.4
Wilkinson, P.M.5
-
23
-
-
1942488208
-
Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy
-
Rudek MA,Sparreboom A,Garrett-Mayer ESet al.Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.Eur J Cancer. 2004;40:1170-1178.
-
(2004)
Eur J Cancer
, vol.40
, pp. 1170-1178
-
-
Rudek, M.A.1
Sparreboom, A.2
Garrett-Mayer, E.S.3
-
24
-
-
77957267066
-
Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass
-
Barpe DR,Rosa DD,Froehlich PE.Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass.Eur J Pharm Sci. 2010;41:458-463.
-
(2010)
Eur J Pharm Sci
, vol.41
, pp. 458-463
-
-
Barpe, D.R.1
Rosa, D.D.2
Froehlich, P.E.3
-
25
-
-
0026737548
-
Epirubicin as a single agent therapy for the treatment of breast cancer: a pharmacokinetic and clinical study
-
Eksborg S,Hardell L,Bengtsson NO,Sjodin M,Elfsson B.Epirubicin as a single agent therapy for the treatment of breast cancer: a pharmacokinetic and clinical study.Med Oncol Tumor Pharmacother. 1992;9:75-80.
-
(1992)
Med Oncol Tumor Pharmacother
, vol.9
, pp. 75-80
-
-
Eksborg, S.1
Hardell, L.2
Bengtsson, N.O.3
Sjodin, M.4
Elfsson, B.5
-
26
-
-
0031860380
-
Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation
-
Gurney HP,Ackland S,Gebski V,Farrell G.Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation.J Clin Oncol. 1998;16:2299-2304.
-
(1998)
J Clin Oncol
, vol.16
, pp. 2299-2304
-
-
Gurney, H.P.1
Ackland, S.2
Gebski, V.3
Farrell, G.4
-
28
-
-
77955802588
-
Estimating the glomerular filtration rate in obese adult patients for drug dosing
-
Pai MP.Estimating the glomerular filtration rate in obese adult patients for drug dosing.Adv Chronic Kidney Dis. 2010;17:e53-e62.
-
(2010)
Adv Chronic Kidney Dis
, vol.17
-
-
Pai, M.P.1
-
29
-
-
63449109827
-
Estimation of creatinine clearance in morbidly obese patients
-
Demirovic JA,Pai AB,Pai MP.Estimation of creatinine clearance in morbidly obese patients.Am J Health Syst Pharm. 2009;66:642-648.
-
(2009)
Am J Health Syst Pharm
, vol.66
, pp. 642-648
-
-
Demirovic, J.A.1
Pai, A.B.2
Pai, M.P.3
-
30
-
-
44549088304
-
Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study
-
Wright JD,Tian C,Mutch DGet al.Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study.Gynecol Oncol. 2008;109:353-358.
-
(2008)
Gynecol Oncol
, vol.109
, pp. 353-358
-
-
Wright, J.D.1
Tian, C.2
Mutch, D.G.3
-
31
-
-
66149190687
-
A universal formula based on cystatin C to perfrom individual dosing of carboplatin in normal weight, underweight, and obese patients
-
Schmitt A,Gladieff L,Lansiaux Aet al.A universal formula based on cystatin C to perfrom individual dosing of carboplatin in normal weight, underweight, and obese patients.Clin Cancer Res. 2009;15:3633-3639.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 3633-3639
-
-
Schmitt, A.1
Gladieff, L.2
Lansiaux, A.3
-
32
-
-
34548119532
-
Pharmacokinetics of doxorubicin and etoposide in a morbidly obese pediatric patient
-
Ritzmo C,Soderhall S,Karlen J,Nygren H,Eksborg S.Pharmacokinetics of doxorubicin and etoposide in a morbidly obese pediatric patient.Pediatr Hematol Oncol. 2007;24:437-445.
-
(2007)
Pediatr Hematol Oncol
, vol.24
, pp. 437-445
-
-
Ritzmo, C.1
Soderhall, S.2
Karlen, J.3
Nygren, H.4
Eksborg, S.5
-
33
-
-
67349169750
-
Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study
-
Thompson PA,Rosner GL,Matthay KKet al.Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study.Cancer Chemother Pharmacol. 2009;64:243-251.
-
(2009)
Cancer Chemother Pharmacol
, vol.64
, pp. 243-251
-
-
Thompson, P.A.1
Rosner, G.L.2
Matthay, K.K.3
-
34
-
-
0036161278
-
Peak plasma concentrations of doxorubicin in children with acute lympoblastic leukemia or non-Hodkin lymphoma
-
Hempel G,Flege S,Wurthwein G,Boos J.Peak plasma concentrations of doxorubicin in children with acute lympoblastic leukemia or non-Hodkin lymphoma.Cancer Chemother Pharmacol. 2002;49:133-141.
-
(2002)
Cancer Chemother Pharmacol
, vol.49
, pp. 133-141
-
-
Hempel, G.1
Flege, S.2
Wurthwein, G.3
Boos, J.4
-
35
-
-
0037962010
-
Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma
-
Meyerhardt JA,Catalano PJ,Haller DGet al.Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma.Cancer. 2003;98:484-495.
-
(2003)
Cancer
, vol.98
, pp. 484-495
-
-
Meyerhardt, J.A.1
Catalano, P.J.2
Haller, D.G.3
-
36
-
-
33644846283
-
Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089
-
Haller DG,Catalano PJ,Macdonald JSet al.Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.J Clin Oncol. 2005;23:8671-8678.
-
(2005)
J Clin Oncol
, vol.23
, pp. 8671-8678
-
-
Haller, D.G.1
Catalano, P.J.2
Macdonald, J.S.3
-
37
-
-
77950628999
-
Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice
-
Behan JW,Avramis VI,Yun JP,Louie SG,Mittelman SD.Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice.Pharmacol Res. 2010;61:385-390.
-
(2010)
Pharmacol Res
, vol.61
, pp. 385-390
-
-
Behan, J.W.1
Avramis, V.I.2
Yun, J.P.3
Louie, S.G.4
Mittelman, S.D.5
|